scanX
Alembic Pharmaceuticals

Alembic Pharmaceuticals

1,000.40
+2.90
(0.29%)
Market Cap
19,664.20 Cr
EPS
29.68
PE Ratio
34.66
Dividend Yield
1.10 %
Industry
Healthcare
52 Week High
1,303.90
52 Week Low
725.20
PB Ratio
3.80
Debt to Equity
0.18
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from12 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+50.00 %
+50.00 %
Hold
Hold+41.67 %
+41.67 %
Sell
Sell+8.33 %
+8.33 %

Company News

View All News
Caret
positive
Alembic Pharmaceuticals' Credit Rating Reaffirmed at AA+/Stable with Enhanced Bank Loan Limit2 days ago
CRISIL Ratings Limited has reaffirmed Alembic Pharmaceuticals Limited's AA+/Stable credit rating for its bank loan facilities. The rated amount has been enhanced from Rs. 600 crores to Rs. 800 crores, while the company's overall borrowing limit remains unchanged. The reaffirmation applies to the company's long-term bank loan facilities.
positive
Alembic Pharmaceuticals Receives US FDA Approval for Carbamazepine Extended-Release Tablets2 days ago
Alembic Pharmaceuticals Limited received final approval from the US FDA for its Carbamazepine Extended-Release Tablets USP in 100 mg, 200 mg, and 400 mg strengths. The approved drug is therapeutically equivalent to Novartis' Tegretol-XR and is indicated for use as an anticonvulsant and for treating pain associated with trigeminal neuralgia. The tablets have an estimated market size of US$ 71 million for twelve months ending March 2025. With this approval, Alembic now has a total of 225 ANDA approvals from the USFDA, comprising 202 final approvals and 23 tentative approvals.

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,702.20
#1 4,08,414.80
35.66
#1 54,729.00
12.06
#1 10,980
-18.99
55.97
Divis Laboratories
6,584.00
1,74,784.50
79.73
9,712.00
0.89
2,191
23.05
40.37
Cipla
1,572.00
1,26,971.70
23.53
28,409.50
7.12
5,291
9.88
70.77
Torrent Pharmaceuticals
3,622.90
1,22,615.40
60.75
11,539.40
6.99
1,911
19.91
72.46
Dr Reddys Laboratories
1,287.40
1,07,442.70
#1 18.90
33,741.20
16.73
5,725
1.26
54.50
Mankind Pharma
2,541.60
1,04,899.10
60.41
12,744.20
19.57
2,007
-10.91
52.39
Zydus Life Science
980.10
98,621.00
21.20
23,511.00
13.82
4,615
-0.19
54.96
Lupin
1,960.50
89,535.10
27.57
22,909.50
#1 19.94
3,306
#1 112.49
53.75
Abbott
32,895.00
69,899.60
49.39
6,684.70
10.80
1,414
27.83
42.22
Aurobindo Pharma
1,127.00
65,456.30
18.95
31,378.10
17.55
3,366
-0.50
47.15

Automatic Screeners on ScanX

Community
Day 1 Unusual Volume
Community
Resistance 1 Breached
Forecast
Actual
Growth Rate
Revenue Growth
7.32 %
Net Income Growth
-5.49 %
Cash Flow Change
-89.05 %
ROE
-12.21 %
ROCE
6.31 %
EBITDA Margin (Avg.)
1.82 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
504
582
1,003
918
630
737
880
777
742
648
797
840
854
863
1,129
1,022
930
952
1,241
1,210
1,243
1,342
1,460
1,317
1,306
1,328
1,313
1,291
1,426
1,263
1,475
1,510
1,407
1,498
1,605
1,634
1,521
1,564
1,678
1,703
1,784
Expenses
405
478
629
532
484
580
702
632
606
547
610
653
680
712
825
776
749
757
895
884
926
934
1,014
949
960
1,090
1,054
1,030
1,268
1,255
1,244
1,274
1,203
1,288
1,387
1,364
1,257
1,325
1,409
1,433
1,498
EBITDA
99
103
375
386
146
158
178
146
136
102
187
188
174
151
305
246
181
195
346
326
318
408
447
368
346
238
259
261
158
9
231
236
205
210
218
269
263
239
270
270
286
Operating Profit %
19 %
18 %
37 %
42 %
23 %
21 %
20 %
19 %
18 %
16 %
23 %
22 %
20 %
18 %
27 %
24 %
19 %
20 %
28 %
27 %
23 %
30 %
30 %
28 %
25 %
18 %
18 %
19 %
10 %
1 %
16 %
16 %
14 %
13 %
13 %
16 %
17 %
15 %
15 %
15 %
15 %
Depreciation
11
13
13
22
24
19
21
21
22
22
26
26
32
28
29
29
30
35
36
42
44
42
44
47
51
53
55
56
123
67
68
67
74
66
68
69
70
69
71
70
69
Interest
0
1
1
1
2
1
1
1
2
1
0
1
1
2
6
6
5
5
7
7
8
7
5
2
3
2
5
4
7
9
12
15
14
14
16
15
11
13
19
22
25
Profit Before Tax
89
91
362
364
120
137
157
124
112
79
161
161
141
122
270
211
146
155
303
276
266
360
398
318
292
183
200
201
29
-67
151
155
116
130
135
185
183
157
180
178
192
Tax
18
19
73
95
29
33
37
37
19
12
39
30
47
32
70
42
23
36
52
49
62
66
73
33
49
24
36
29
7
-2
18
33
-36
9
-2
4
5
23
27
40
35
Net Profit
70
72
289
269
91
104
120
87
93
67
122
131
94
90
200
169
124
120
250
227
204
293
325
286
243
158
164
172
22
-66
133
122
153
121
137
180
178
135
153
138
157
EPS in ₹
3.73
3.72
15.30
14.26
4.82
5.50
6.36
4.59
4.94
3.54
6.45
6.93
4.98
4.80
10.61
9.01
6.58
6.56
13.06
12.42
11.93
15.99
17.24
14.88
12.75
8.37
8.34
8.74
1.11
-3.35
6.78
6.20
7.76
6.14
6.95
9.23
9.07
6.84
7.79
7.01
7.98
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
1,641
2,429
2,689
3,941
4,778
5,989
6,709
7,122
6,183
6,446
7,773
Fixed Assets
547
708
799
993
1,159
1,552
1,788
1,798
2,398
2,547
2,524
Current Assets
891
1,511
1,373
1,825
1,958
2,463
2,652
2,861
2,910
3,079
4,088
Capital Work in Progress
83
93
396
1,010
1,551
1,846
2,183
2,304
601
524
837
Investments
0
53
50
42
49
18
236
118
96
93
127
Other Assets
1,011
1,575
1,444
1,896
2,019
2,573
2,502
2,902
3,087
3,282
4,285
Total Liabilities
1,641
2,429
2,689
3,941
4,778
5,989
6,709
7,122
6,183
6,446
7,773
Current Liabilities
684
747
693
1,144
1,490
1,752
1,281
1,717
1,637
1,455
2,412
Non Current Liabilities
72
84
94
576
570
1,047
361
168
175
172
171
Total Equity
885
1,597
1,902
2,220
2,718
3,190
5,067
5,238
4,371
4,818
5,190
Reserve & Surplus
847
1,560
1,865
2,182
2,681
3,182
5,028
5,198
4,331
4,779
5,152
Share Capital
38
38
38
38
38
38
39
39
39
39
39
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
3
417
-286
-69
115
-127
26
-37
14
45
-37
Investing Activities
-256
-307
-486
-884
-756
-731
-840
-372
-448
-321
-568
Operating Activities
172
948
329
312
812
449
1,463
552
724
803
88
Financing Activities
87
-224
-129
503
59
155
-597
-217
-262
-438
444
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
69.48 %
69.48 %
69.48 %
69.48 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.67 %
69.67 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
4.52 %
4.46 %
4.32 %
3.94 %
4.17 %
3.94 %
3.96 %
DIIs
10.92 %
11.17 %
11.36 %
11.56 %
11.69 %
12.06 %
12.43 %
12.76 %
13.31 %
13.40 %
13.93 %
14.50 %
15.38 %
15.47 %
16.05 %
16.06 %
16.43 %
16.46 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
10.99 %
10.78 %
11.43 %
9.57 %
9.22 %
8.91 %
9.12 %
9.21 %
9.08 %
8.98 %
8.24 %
8.00 %
7.41 %
7.48 %
7.36 %
7.26 %
7.07 %
7.01 %
Others
8.61 %
8.57 %
7.73 %
9.39 %
9.47 %
9.41 %
8.84 %
8.42 %
8.00 %
8.01 %
8.22 %
3.37 %
3.14 %
3.13 %
3.04 %
2.90 %
2.88 %
2.89 %
No of Share Holders
0
0
99,809
1,01,686
1,23,059
1,10,038
1,06,437
1,01,457
1,03,811
97,607
89,552
85,212
76,567
74,829
91,429
93,944
91,336
89,013

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 4 4 5.5 10 14 10 8 11 11
Dividend Yield (%) 0.00 0.73 0.74 1.03 1.04 1.89 2.13 0.81 1.18 1.1

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
05 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 05 Aug 2025 1,031.40 1,000.40
05 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 05 Aug 2025 982.70 1,000.40
29 Jul 2025 DIVIDEND Dividend
₹ 11.00 /share
 29 Jul 2025 905.45 1,000.40
06 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 06 May 2025 849.90 905.45
03 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 03 Feb 2025 1,029.95 937.10
07 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 07 Nov 2024 1,182.75 1,139.20
22 Jul 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 22 Jul 2024 845.20 1,079.55
15 Jul 2024 DIVIDEND Dividend
₹ 11.00 /share
 15 Jul 2024 1,001.85 984.60
28 Jul 2023 DIVIDEND Dividend
₹ 8.00 /share
 28 Jul 2023 560.55 732.15
18 Aug 2022 DIVIDEND Dividend
₹ 10.00 /share
 17 Aug 2022 781.50 656.10
21 Jul 2021 DIVIDEND Dividend
₹ 14.00 /share
 19 Jul 2021 983.60 939.65

Announcements

Announcement under Regulation 30 (LODR)-Credit Rating2 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release2 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
Announcement under Regulation 30 (LODR)-Change in Management7 days ago
Board Meeting Intimation for Board Meeting To Consider Unaudited Financial Results For The Quarter Ended 30Th June 20257 days ago
Announcement under Regulation 30 (LODR)-Change in ManagementJul 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 07, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 07, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 04, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 03, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 02, 2025
Volume MovementJul 01, 2025
Clarification sought from Alembic Pharmaceuticals LtdJul 01, 2025
Alembic Pharmaceuticals Receives USFDA Final Approval For Doxorubicin Hydrochloride Liposome InjectionJun 29, 2025
Closure of Trading WindowJun 26, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJun 25, 2025
Alembic Pharmaceuticals Limited Has Received Establishment Inspection Report (EIR) For Its API-III Facility At KarakhadiJun 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 18, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Jun 17, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 17, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jun 16, 2025
Submission Of Notice Of The 15Th Annual General Meeting Of The CompanyJun 16, 2025
Submission Of Notice Of The 15Th Annual General Meeting Of The CompanyJun 16, 2025
Reg. 34 (1) Annual Report.Jun 16, 2025
Announcement under Regulation 30 (LODR)-Credit RatingJun 12, 2025
Announcement under Regulation 30 (LODR)-Credit RatingJun 12, 2025
Intimation Of Record Date For Payment Of Dividend On Equity Shares For The Financial Year Ended 31St March 2025Jun 11, 2025
USFDA Inspection At Alembic Pharmaceuticals LimitedS API - I & II Facility Located At Panelav.May 31, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 23, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 23, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 21, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 16, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2025
Please Find Attached Herewith Copy Of Newspaper AdvertisementMay 15, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 15, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 15, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 13, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 12, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 06, 2025
Announcement Under Regulation 30 Of SEBI LODRMay 06, 2025
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sMay 06, 2025
Financial Results For The Quarter And Financial Year Ended 31St March 2025May 06, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 06, 2025

Technical Indicators

RSI(14)
Neutral
50.20
ATR(14)
Volatile
30.03
STOCH(9,6)
Neutral
56.85
STOCH RSI(14)
Neutral
20.86
MACD(12,26)
Bearish
-2.70
ADX(14)
Strong Trend
33.29
UO(9)
Bearish
44.03
ROC(12)
Uptrend And Accelerating
1.50
WillR(14)
Neutral
-60.33
Bearish
3
Neutral
4
Bullish
2

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Edelweiss Mid Cap Direct Plan-Growth
0.32%
-183527
-0.21%
-0.17%
Edelweiss Multi Cap Fund Direct - Growth
0.53%
-80734
-0.32%
-0.24%
Edelweiss Flexi Cap Fund Direct-Growth
0.43%
-80272
-0.32%
-0.24%
Mirae Asset Healthcare Fund Direct - Growth
0.97%
-30000
-0.13%
0.02%
DSP ELSS Tax Saver Fund Direct Plan-Growth
0.86%
14504
0.01%
0.11%
UTI Healthcare Fund Direct-Growth
1.03%
-1763
-0.03%
-0.12%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.29%
1584
-0.01%
0.01%
Nippon India Nifty 500 Equal Weight Index Fund Direct-Growth
0.21%
985
0.01%
0.02%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.29%
717
-0.01%
0.01%
Navi Nifty Smallcap250 Momentum Quality 100 Index Fund Direct - Growth
0.00%
-606
-0.47%
-0.44%
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
0.29%
265
-0.01%
0.00%
SBI Nifty Smallcap 250 Index Fund Direct - Growth
0.29%
262
-0.01%
0.01%
Tata Nifty MidSmall Healthcare Index Fund Direct - Growth
0.98%
226
-0.05%
0.09%
HDFC Nifty500 Multicap 50:25:25 Index Fund Direct-Growth
0.07%
-112
-0.01%
0.00%
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth
0.29%
99
-0.01%
0.01%
Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth
0.98%
-78
-0.05%
0.08%
Kotak Nifty Smallcap 250 Index Fund Direct-Growth
0.29%
58
-0.01%
0.01%
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
0.29%
51
-0.01%
0.01%
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth
0.29%
-39
-0.01%
0.00%
Motilal Oswal Nifty 500 Index Fund Direct - Growth
0.03%
37
0.00%
0.00%
HDFC BSE 500 Index Fund Direct - Growth
0.03%
18
0.00%
0.00%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.43%
14
-0.01%
0.05%
SBI Nifty 500 Index Fund Direct-Growth
0.03%
-14
0.00%
0.00%
Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth
0.07%
-11
-0.01%
0.00%
Groww Nifty Total Market Index Fund Direct - Growth
0.03%
10
0.00%
0.00%

About Alembic Pharmaceuticals

Alembic Pharmaceuticals is an India-based company that manufactures and markets generic pharmaceutical products globally. It operates in India Formulations, International Generics, and Active Pharmaceutical Ingredients (API) segments. The company has state-of-the-art research and manufacturing facilities approved by regulatory authorities, including the US FDA. Alembic produces a range of generics across chronic segments, including Dermatology, Anti-Infective, Cardiology, and Anti-Diabetic therapies. The company has manufacturing facilities in Gujarat and Sikkim, with research and development centers in Vadodara, Hyderabad, and New Jersey. Alembic has expanded its operations through acquisitions, joint ventures, and international subsidiaries, focusing on developing and marketing generic drugs in various global markets.
Website
https://www.alembicpharmaceuticals.com/
Chairperson NameChirayu R Amin
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Intraday Screeners
Technical Screeners
Candlestick Screeners
Price & Volume Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104